ejpmr, 2024, 11(8), 182-188

SJIF Impact Factor 7.065

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

A REVIEW ON RISK OF MYOCARDIAL INFARCTION FOLLOWING COVID-19 INFECTION

Dr. Srinivasarao Varagani[1]*, Dr. Arepogu Ramesh[2], Dr. C. Sravani[3], Alapati Sathya Sai Guptha[4], Dr. Fizia Mohammadi[5], Haleema Kauser[6] and Shubamalya L. G.[7]

[1]Duty Medical Officer, Viswabharathi Super Speciality Hospital, Guntur, varaganisrinivasarao1998@gmail.com
[2]PHARM.D, Rameshsarepogu777@gmail.com
[3]PHARM.D, St. John's College of Pharmaceutical Sciences, Yerrakota, Yemmiganur, Andhrapradesh. csravani0105@gmail.com
[4]PHARM.D, Smt Sarojini Ramulamma College of Pharmacy, Mahabubnagar, Telangana alapatisathyasai@gmail.com
[5]Assistant Professor, Department of Pharmacy Practice East Point College of Pharmacy, Bangalore, Karnataka, fiziafaizan@gmail.com
[6]PHARM.D, Holy Mary Institute of Science and Technology, Keesara, Telangana kauserh2907@gmail.com
[7]PHARM.D, RAO'S College of Pharmacy, Nellore drshubamalyapharmd@gmail.com

***Corresponding Author: Dr. Srinivasarao Varagani**

Duty Medical Officer, Viswabharathi Super Speciality Hospital, Guntur.

Email id: varaganisrinivasarao1998@gmail.com,

Article Received on 15/06/2024 **Article Revised on 05/07/2024** **Article Accepted on 25/07/2024**

ABSTRACT

The COVID-19 pandemic produced by SARS-CoV-2 has had a major influence on cardiovascular health worldwide. New research indicates that those who have been afflicted have a higher risk of myocardial infarction (MI). This review summarizes recent research to clarify the complex pathways of MI following COVID-19 infection. The direct impact of viral invasion on the heart, systemic inflammation that causes endothelial dysfunction and hypercoagulability, and the aggravation of conventional cardiovascular risk factors are some of the important subjects discussed. Critical evaluation is given to the diagnostic difficulties and developments in biomarkers (e.g., troponin, CRP) and imaging modalities (echocardiography, CT angiography) for evaluating MI in COVID-19 patients. The review's conclusions highlight the significance of customized diagnostic strategies and focused treatment approaches in reducing the progressive cardiovascular effects of COVID-19. It also discusses future avenues for study and the consequences for public health policy, highlighting the necessity of integrated healthcare methods to maximize cardiovascular care in the aftermath of the epidemic.

KEYWORDS: COVID-19, SARS-CoV-2, myocardial infarction, cardiovascular complications, biomarkers, imaging modalities, endothelial dysfunction, inflammation, hypercoagulability, diagnostic challenges, therapeutic strategies.

INTRODUTION

The late-2019 COVID-19 pandemic had a significant impact on social dynamics, economy, and worldwide health systems. This infectious disease, which was brought on by the new coronavirus SARS-CoV-2, spread swiftly throughout the world, igniting enormous public health reactions and bringing attention to the virus's varied effects beyond respiratory illness. COVID-19 has many effects, but one that stands out is that it has important consequences for cardiovascular health.[1,2,]

It was clear early in the pandemic that COVID-19 posed serious hazards to cardiovascular function in addition to its effects on the respiratory system. Individuals who already had cardiovascular problems such as heart failure, hypertension, or coronary artery disease were more vulnerable to severe sickness and unfavorable outcomes from COVID-19 infection. Further complicating clinical therapy and outcomes is direct cardiac involvement, which includes myocardial damage, arrhythmias, and myocarditis, as revealed by growing research.

The pandemic has had indirect cardiovascular repercussions in addition to acute ones. The management and prevention of cardiovascular disease have been impacted by changes in patient behaviors, delays in normal medical care, and disruptions in the delivery of healthcare. The interaction of cardiovascular risk factors, COVID-19 infection, and long-term cardiovascular consequences highlights the need for continued research and all-encompassing public health approaches.[3]

A number of factors make the risk of myocardial infarction (heart attack) in COVID-19 individuals extremely concerning:

1. **Direct Cardiovascular Effects**: COVID-19 has the potential to cause arrhythmias, myocarditis, and other cardiac problems by directly affecting the cardiovascular system. These may make a myocardial infarction more likely.
2. **Indirect Effects**: In patients with underlying risk factors such hypertension, diabetes, or obesity, the systemic inflammatory response brought on by COVID-19 may destabilize pre-existing cardiovascular diseases or cause new cardiovascular events.
3. **Hypercoagulable State**: COVID-19 has been linked to a hypercoagulable state, which raises the risk of thrombosis, or blood clots. This may have an impact on the coronary arteries and cause myocardial infarction.
4. **Respiratory Compromise**: Intensive care and mechanical ventilation are frequently necessary for severe COVID-19 cases, which can put a load on the cardiovascular system and raise the risk of myocardial infarction, particularly in people with impaired heart function.
5. **Long-Term Effects**: Some people have COVID-19 long-term repercussions, such as persistent cardiovascular problems such myocardial inflammation or damage, which raises the possibility of another myocardial infarction.[4,5]

IMPORTANCE OF STUDYING MYOCARDIAL INFARCTION (MI) POST COVID-19 INFECTION

It is important to research myocardial infarction (MI) following COVID-19 infection for a number of reasons:

1. **Understanding the Mechanisms**: The direct effects of COVID-19 on the heart and the systemic inflammatory response are just two of the ways that research can clarify how the virus affects cardiovascular health. This information can direct treatment plans and enhance patient results.
2. **Risk Assessment**: Early intervention and preventive measures are aided by identifying individuals who are more susceptible to MI following COVID-19 infection. For vulnerable groups, such as those with pre-existing cardiovascular diseases, this is especially crucial.
3. **Long-Term Cardiovascular Health**: Individuals who have recovered from COVID-19 may be at risk for developing myocarditis or persistent inflammation, which can worsen their cardiovascular health over time and increase their risk of MI and other heart problems. Understanding and controlling these long-term hazards can be aided by researching MI after COVID-19.
4. **Healthcare Planning**: By providing appropriate monitoring and specialized care for afflicted individuals, insights into post-COVID-19 cardiovascular problems can help guide healthcare planning and budget allocation.
5. **Public Health Strategies**: Research on MI following COVID-19 informs immunization programs, protocols for treating COVID-19 patients with comorbid cardiovascular diseases, and suggestions for follow-up surveillance.[6,7]

EPIDEMIOLOGY OF COVID-19 AND MYOCARDIAL INFARCTION

Globally, the epidemiology of COVID-19 and myocardial infarction (MI) can be measured using a variety of statistical techniques. Research has indicated that the frequency of acute myocardial damage or infarction varies greatly among hospitalized COVID-19 patients, ranging from roughly 7% to 25%. Patient demographics, underlying cardiovascular risk factors, and the severity of the COVID-19 sickness all have an impact on this variation. According to these variables, the incidence of MI in COVID-19 individuals varies accordingly. Precise worldwide incidence rates are not consistently recorded because of variations in reporting guidelines and healthcare practices.

Cardiovascular problems, including MI, have been documented in severe COVID-19 cases in certain regions, such as India, but precise number data may be lacking. These observations reflect broader global trends. These figures demonstrate how seriously COVID-19 affects cardiovascular health and how crucial it is to comprehend and treat cardiac problems in relation to this virus. Prolonged investigation and all-encompassing medical approaches are necessary to reduce the likelihood of MI and enhance outcomes for COVID-19 patients globally.[8,9]

PATHOPHYSIOLOGY OF MYOCARDIAL INFARCTION IN COVID-19

Complex interactions between the virus and the circulatory system result in a variety of pathways that might cause myocardial damage in the pathogenesis of myocardial infarction (MI) in COVID-19.

1. **Direct Viral Entry and Myocardial Injury**
   - **ACE2 Receptors**: Heart tissue is rich in angiotensin-converting enzyme 2 (ACE2) receptors, which allow SARS-CoV-2, the virus that causes COVID-19, to enter cells. Direct viral replication and myocardial injury can result from viral entrance into cardiac cells.

2. **Inflammatory Response and Cytokine Storm**
   - **Systemic Inflammation**: COVID-19 causes a strong inflammatory response throughout the body, which is commonly referred to as a cytokine storm. Myocardial ischemia and infarction can be caused by the excessive release of pro-inflammatory cytokines, such as interleukin-6 and tumor necrosis factor-alpha, which can also destabilize coronary plaques, induce microvascular thrombosis, and promote endothelial dysfunction.[10,11,12]

3. **Endothelial Dysfunction and Thrombosis**
   - **Endothelial Damage**: Endothelial dysfunction is defined by reduced vasodilation, elevated vascular permeability, and activation of procoagulant pathways. This is caused by direct viral infection of endothelial cells.
   - **Thrombotic Events**: A hypercoagulable condition is produced by endothelial dysfunction and the inflammatory response, which encourages the formation of thrombus in coronary arteries. These thrombotic episodes may block blood flow, which could result in an acute myocardial infarction or ischemia.[13,14]

4. **Microvascular Dysfunction**
   - **Microthrombi**: COVID-19 is linked to the development of microthrombi in the body's tiny vessels, particularly the heart. Impaired myocardial perfusion is a result of microvascular dysfunction, which exacerbates ischemia injury and may cause MI.

5. **Indirect Cardiovascular Effects**
   - **Hemodynamic Instability**: Acute respiratory distress syndrome (ARDS), hypoxia, and multiorgan failure can result in hemodynamic instability in severe COVID-19 instances. The cardiovascular system may be strained by these systemic effects, which may worsen the myocardial oxygen demand-supply imbalance and increase the risk of MI.

6. **Pre-existing Cardiovascular Conditions**
   - **Exacerbation of Underlying Disease**: Individuals who already have a history of cardiovascular disease, such as hypertension or coronary artery disease, are more susceptible to the COVID-19's effects on the heart. The virus may intensify pre-existing disease, resulting in MI or other acute coronary events.[15,16]

The complex interaction of direct viral effects on cardiac cells, systemic inflammation, endothelial dysfunction, thrombosis, microvascular abnormalities, and worsening of underlying cardiovascular diseases underlies the pathogenesis of myocardial infarction in COVID-19. It is imperative to comprehend these pathways in order to devise focused medications and interventions aimed at alleviating the cardiovascular problems linked to COVID-19.

CLINICAL PRESENTATION OF MYOCARDIAL INFARCTION IN COVID-19 PATIENTS

Symptoms	Atypical Presentations of MI	Overlap with COVID-19 Symptoms
Chest Pain	Confusion or Delirium	Shortness of Breath
Shortness of Breath	Abdominal Pain	Fatigue
Fatigue	Fatigue, Weakness	Chest Pain (may be less pronounced)
Nausea and Vomiting	Syncope (Fainting)	Fever, Loss of Smell or Taste
Sweating	Nausea and Vomiting	Muscle Aches, Headache
Dizziness or Lightheadedness	Back Pain, Jaw Pain	Sore Throat
Anxiety	Palpitations	Gastrointestinal Symptoms (e.g., diarrhea)

RISK FACTORS FOR MYOCARDIAL INFARCTION POST COVID-19

A number of factors can raise the risk of myocardial infarction (MI) after COVID-19, both by aggravating established cardiovascular risk factors and by unique COVID-19-related mechanisms:

Traditional Cardiovascular Risk Factors Exacerbated by COVID-19: Hypertension: Systemic inflammation and endothelial dysfunction brought on by COVID-19 can worsen hypertension and raise the risk of MI.

1. **Diabetes Mellitus**: Patients with diabetes may have worse glycemic control, which raises their risk of MI. Hyperglycemia and systemic inflammation linked to COVID-19 can exacerbate this condition.
2. **Dyslipidemia**: Dyslipidemia can be made worse by COVID-19-related metabolic abnormalities and inflammatory reactions, which can lead to atherosclerosis and consequent MI.
3. **Obesity**: Because obesity is associated with metabolic dysregulation and chronic inflammation, COVID-19 individuals who are obese are more likely to experience cardiovascular problems, such as MI.
4. **Smoking**: Smoking can exacerbate the cardiovascular effects of COVID-19, speeding up atherosclerosis and raising the risk of MI. It can also cause systemic inflammation and respiratory impairment.[17,18,19]

Specific Risk Factors Associated with COVID-19-Induced MI

1. **Direct Myocardial Injury**: By invading myocardial cells and causing myocarditis or stress-induced cardiomyopathy, which are conditions that increase the risk of MI, COVID-19 can directly cause myocardial injury.
2. **Hypercoagulable State**: The risk of thrombotic events, such as coronary thrombosis leading to MI, is increased by COVID-19-induced hypercoagulability and endothelial dysfunction.
3. **Cytokine Storm**: A severe COVID-19 infection may cause an overabundance of inflammatory cytokines to be released into the bloodstream, which can lead to endothelial damage, plaque instability, and MI.

4. **Microvascular Dysfunction**: Even in the absence of type 2 MI, or obstructive coronary artery disease, COVID-19 can impair microvascular function, resulting in myocardial ischemia.
5. **Long-Term Inflammatory Consequences**: Endothelial dysfunction and a prothrombotic condition can be sustained by persistent inflammation following COVID-19, which increases the risk of MI.[20,21,22]

Assessing and controlling the risk of MI in recuperating patients requires an understanding of the interaction between particular mechanisms of COVID-19-induced myocardial injury and standard cardiovascular risk factors that are amplified by the virus. Thorough risk evaluation, prompt intervention, and customized management approaches are necessary to reduce the long-term cardiovascular effects of COVID-19 infection.

ROLE OF BIOMARKERS (TROPONIN, CRP) IN DIAGNOSING MI POST-COVID-19

1. **Troponin**: Crucial in the diagnosis of myocardial infarction (MI), troponin is a sensitive biomarker for myocardial damage. Elevated troponin levels in COVID-19 patients may be a sign of stress cardiomyopathy (Takotsubo syndrome), ischemia brought on by hypoxemia or hypercoagulability, or direct viral myocarditis
2. **CRP (C-reactive protein)**: Patients with COVID-19 who have cardiac involvement may have high CRP, a sign of systemic inflammation. Increased CRP levels can assist determine the extent of cardiac damage and its prognosis, as well as signify persistent inflammation.[23,24]

IMAGING MODALITIES FOR ASSESSMENT OF MI POST-COVID-19

1. **Echocardiography**
   - **Transthoracic Echocardiography (TTE)**: This method is frequently employed to evaluate the structure and function of the heart. It is capable of identifying anomalies such myocarditis symptoms, pericardial effusion, regional wall motion abnormalities, and left ventricular failure.
   - **Transesophageal Echocardiography (TEE)**: TEE is more sensitive in identifying intracardiac thrombi or emboli in patients who are suspected of having MI. It also offers detailed pictures of the heart.

2. **CT Angiography (CTA)**
   - **Coronary CT Angiography**: This non-invasive imaging technique looks at the coronary arteries to check for abnormalities and obstructive coronary artery disease (CAD). After COVID-19, it can detect coronary artery stenosis or occlusions in individuals suspected of MI.
   - **CT Perfusion Imaging**: This method complements coronary architecture by evaluating myocardial perfusion and identifying regions of myocardial ischemia or infarction.

Myocardial damage in COVID-19 patients is primarily diagnosed by biomarkers such as troponin and CRP, although CT angiography and echocardiography are useful imaging modalities for evaluating the structure, function, and coronary architecture of the heart in suspected MI cases. Combining these diagnostic techniques makes it easier to implement management plans that are customized to meet the needs of each patient in a timely manner.[25,26,27]

MANAGEMENT

Because the virus affects cardiovascular health and there may be overlap in symptoms, managing myocardial infarction (MI) in COVID-19 patients poses special complications. The following are important factors to take into account for treatment plans and long-term results:

Treatment Strategies for MI in COVID-19 Patients

1. **Early Recognition and Diagnosis**: Early evaluation with diagnostic techniques such as ECG, troponin levels, and imaging is critical due to the overlap in symptoms (e.g., chest pain and shortness of breath).
2. **Pharmacological Management**: It is still essential to use drugs such as aspirin, beta-blockers, statins, antiplatelet medicines (like clopidogrel), and anticoagulants (like heparin), with dosage adjustments made in accordance with the patient's clinical condition and COVID-19 severity.
3. **Invasive Strategies**: Considering COVID-19 infection, coronary angiography and percutaneous coronary intervention (PCI) should weigh the risks of procedural complications against the advantages of revascularization.
4. **Monitoring and Supportive Care**: It is essential to continuously evaluate cardiac state, oxygenation, and hydration management. Potential COVID-19-related consequences, such as acute respiratory distress syndrome (ARDS), should also be carefully considered.[28,29,30]

Long-Term Cardiovascular Outcomes and Prognosis

1. **Cardiac Complications**: COVID-19 has been linked to an increased risk of myocarditis and myocardial damage, which may have an impact on the prognosis and long-term recovery following a MI.
2. **Risk of Recurrence**: Individuals who have MI during COVID-19 may be at continuous risk for cardiovascular events, which calls for long-term pharmaceutical treatment, lifestyle adjustments, and cardiac rehabilitation.
3. **Impact on Mortality**: Research indicates that COVID-19 infection in MI patients may raise the chance of death, highlighting the necessity of thorough monitoring and treatment of lingering cardiovascular hazards.
4. **Recovery and Rehabilitation**: Following a MI, early cardiac rehabilitation is crucial to maximizing

recuperation and minimizing the long-term effects on cardiovascular function.

Treating MI in COVID-19 patients necessitates a multidisciplinary strategy that strikes a balance between the infection's complexity and the myocardial infarction's acute needs. In order to reduce the cardiovascular risks associated with both illnesses, quick intervention, efficient comorbidity management, and systematic follow-up are essential for the long-term prognosis.[31,32]

FUTURE DIRECTIONS

Diagnostic Advances

1. **Biomarkers Beyond Troponin and CRP**: New biomarkers that can offer more precise insights into the mechanisms of cardiac injury in COVID-19 patients are likely to be the subject of future research. These may include indicators of endothelial dysfunction, inflammation, or myocardial stress.
2. **Point-of-Care Testing**: The creation of quick, on-site diagnostic tests for MI biomarkers that can help in various healthcare environments, such as isolated or resource-constrained places, by enabling early identification and intervention.
3. **Advanced Imaging Technologies**: Ongoing improvements in cardiac imaging, such as the use of artificial intelligence (AI) to improve the interpretation of coronary CT angiography and echocardiography, which can be used to diagnose MI and evaluate myocardial function more accurately and efficiently.[33,34,35]

Therapeutic Innovations

1. **Tailored Therapies**: Individualized therapy plans designed to maximize benefits and reduce side effects in patients recovering from COVID-19 MI. These plans are based on unique biomarker profiles, imaging results, and genetic variables.
2. **COVID-19 Specific Guidelines**: The creation of protocols and recommendations specifically designed to manage MI within the framework of COVID-19, taking into account certain pathophysiological features as inflammation and hypercoagulability.

Research Areas

1. **Long-Term Cardiovascular Sequelae**: More research is needed to determine the long-term cardiovascular effects of COVID-19, including the likelihood of recurrent MI, the permanence of myocardial injury, and the implications for cardiovascular health after recovery.
2. **Impact of Vaccination**: Studies looking at how the COVID-19 vaccine affects cardiovascular health, including possible preventive effects against myocardial damage and long-term consequences in those who have already contracted the virus.

Public Health and Policy

1. **Healthcare Infrastructure Preparedness**: Forcing improvements to the world's healthcare systems in order to improve the ability to promptly diagnose, treat, and rehabilitate MI and other cardiovascular problems following COVID-19.
2. **Education and Awareness**: Raising public and healthcare professional knowledge of the cardiovascular risks linked to COVID-19 infection as well as the significance of early detection and treatment.[36,37]

CONCLUSION

This study concludes by highlighting the important and complex association between the risk of myocardial infarction (MI) and COVID-19 infection. Emerging data has continuously demonstrated during the COVID-19 pandemic that the virus not only affects the respiratory system but also offers serious risks to cardiovascular health. The intricate interactions between viral invasion, systemic inflammation, endothelial dysfunction, and thrombotic consequences are part of the pathophysiological pathways that underlie COVID-19-induced myocardial damage, and they all work together to increase the risk of MI.

According to epidemiological research, COVID-19 patients have a higher prevalence of MI. These patients frequently appear with both normal and unusual symptoms, which makes it more difficult to diagnose and treat the condition in a timely manner. A customized approach is necessary for the care of MI in these patients, given the distinct problems presented by coagulopathy, myocardial injury, and cytokine storms related to COVID-19.

In order to fully understand the long-term cardiovascular effects of COVID-19, especially how it may affect post-MI outcomes and cardiac rehabilitation techniques, more research is needed. Clinically, early and aggressive cardiovascular monitoring and intervention, along with increased healthcare provider knowledge of the risk of MI in COVID-19 patients, will be essential to reducing unfavorable outcomes and enhancing patient survival.

In conclusion, managing the risk of myocardial infarction is crucial to the overall care of COVID-19 patients, even if the entire range of COVID-19-related cardiovascular problems is still being discovered. To lessen the effect of COVID-19 on cardiovascular health worldwide, future research should concentrate on improving long-term cardiac care, optimizing treatment techniques, and improving risk stratification strategies.

REFERENCES

1. Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents., 2020 Aug; 56(2): 106054.

2. Chakraborty I, Maity P. COVID-19 outbreak: Migration, effects on society, global environment and prevention. Sci Total Environ., 2020 Aug 1; 728: 138882.
3. Vidal-Perez R, Brandão M, Pazdernik M, Kresoja KP, Carpenito M, Maeda S, Casado-Arroyo R, Muscoli S, Pöss J, Fontes-Carvalho R, Vazquez-Rodriguez JM. Cardiovascular disease and COVID-19, a deadly combination: A review about direct and indirect impact of a pandemic. World J Clin Cases, 2022 Sep 26; 10(27): 9556-9572.
4. Alqahtani MS, Abbas M, Alsabaani A, Alqarni A, Almohiy HM, Alsawqaee E, Alshahrani R, Alshahrani S. The Potential Impact of COVID-19 Virus on the Heart and the Circulatory System. Infect Drug Resist., 2022 Mar 22; 15: 1175-1189.
5. Singhania N, Bansal S, Nimmatoori DP, Ejaz AA, McCullough PA, Singhania G. Current Overview on Hypercoagulability in COVID-19. Am J Cardiovasc Drugs, 2020 Oct; 20(5): 393-403.
6. Zuin M, Rigatelli G, Battisti V, Costola G, Roncon L, Bilato C. Increased risk of acute myocardial infarction after COVID-19 recovery: A systematic review and meta-analysis. Int J Cardiol., 2023 Feb 1; 372: 138-143.
7. Del Prete A, Conway F, Della Rocca DG, Biondi-Zoccai G, De Felice F, Musto C, Picichè M, Martuscelli E, Natale A, Versaci F. COVID-19, Acute Myocardial Injury, and Infarction. Card Electrophysiol Clin., 2022 Mar; 14(1): 29-39.
8. ardman A, Zahger D, Orvin K, Oren D, Kofman N, Mohsen J, Tsafrir O, Asher E, Rubinshtein R, Jamal J, Efraim R, Halabi M, Shacham Y, Fortis LH, Cohen T, Klempfner R, Segev A, Beigel R, Matetzky S. Acute myocardial infarction in the Covid-19 era: Incidence, clinical characteristics and in-hospital outcomes-A multicenter registry. PLoS One., 2021 Jun 18; 16(6): e0253524.
9. Rus M, Ardelean AI, Andronie-Cioara FL, Filimon GC. Acute Myocardial Infarction during the COVID-19 Pandemic: Long-Term Outcomes and Prognosis—A Systematic Review. Life, 2024; 14(2): 202.
10. Tolu-Akinnawo O, Adusei Poku F, Elimihele T, League M, Adkins CF, Okafor H. Acute Cardiovascular Complications of COVID-19: A Systematic Review. Cureus, 2023 May 5; 15(5): e38576.
11. Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis., 2021 May; 40(5): 905-919.
12. Nazerian Y, Ghasemi M, Yassaghi Y, Nazerian A, Hashemi SM. Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: Molecular pathways and potential therapeutic options. Int Immunopharmacol, 2022 Dec; 113(Pt B): 109428.
13. Yokota S, Miyamae T, Kuroiwa Y, Nishioka K. Novel Coronavirus Disease 2019 (COVID-19) and Cytokine Storms for More Effective Treatments from an Inflammatory Pathophysiology. J Clin Med., 2021 Feb 17; 10(4): 801.
14. Pelle MC, Zaffina I, Lucà S, Forte V, Trapanese V, Melina M, Giofrè F, Arturi F. Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options. Life (Basel), 2022 Oct 14; 12(10): 1605.
15. Yin J, Wang S, Liu Y, Chen J, Li D, Xu T. Coronary microvascular dysfunction pathophysiology in COVID-19. Microcirculation, 2021 Oct; 28(7): e12718.
16. Henning RJ. Cardiovascular complications of COVID-19 severe acute respiratory syndrome. Am J Cardiovasc Dis. 2022 Aug 15;12(4):170-191
17. Kumar N, Verma R, Lohana P, Lohana A, Ramphul K. Acute myocardial infarction in COVID-19 patients. A review of cases in the literature. Arch Med Sci Atheroscler Dis., 2021 Sep 20; 6: e169-e175.
18. Katsoularis I, Fonseca-Rodríguez O, Farrington P, Lindmark K, Fors Connolly AM. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet, 2021 Aug 14; 398(10300): 599-607.
19. Wilk-Sledziewska K, Sielatycki PJ, Uscinska N, Bujno E, Rosolowski M, Kakareko K, Sledziewski R, Rydzewska-Rosolowska A, Hryszko T, Zbroch E. The Impact of Cardiovascular Risk Factors on the Course of COVID-19. J Clin Med., 2022 Apr 18; 11(8): 2250.
20. Hariyanto TI, Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr., 2020 Sep-Oct; 14(5): 1463-1465.
21. Paruchuri SSH, Farwa UE, Jabeen S, Pamecha S, Shan Z, Parekh R, Lakkimsetti M, Alamin E, Sharma V, Haider S, Khan J, Razzaq W. Myocarditis and Myocardial Injury in Long COVID Syndrome: A Comprehensive Review of the Literature. Cureus, 2023 Jul 25; 15(7): e42444.
22. Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res., 2020 Oct; 194: 101-115. doi: 10.1016/j.thromres.2020.06.029. Epub 2020 Jun 20. Erratum in: Thromb Res., 2021 Aug; 204: 146.
23. Rasmi Y, Mosa OF, Alipour S, Heidari N, Javanmard F, Golchin A, Gholizadeh-Ghaleh Aziz S. Significance of Cardiac Troponins as an Identification Tool in COVID-19 Patients Using Biosensors: An Update. Front Mol Biosci., 2022 Feb 24; 9: 821155.
24. Duca ȘT, Chetran A, Miftode RȘ, Mitu O, Costache AD, Nicolae A, Iliescu-Halițchi D, Halițchi-Iliescu CO, Mitu F, Costache II. Myocardial Ischemia in Patients with COVID-19 Infection: Between Pathophysiological Mechanisms and

Electrocardiographic Findings. Life (Basel), 2022 Jul 8; 12(7): 1015.
25. Adeboye A, Alkhatib D, Butt A, Yedlapati N, Garg N. A Review of the Role of Imaging Modalities in the Evaluation of Viral Myocarditis with a Special Focus on COVID-19-Related Myocarditis. Diagnostics (Basel), 2022 Feb 21; 12(2): 549.
26. Eckert J, Schmidt M, Magedanz A, Voigtländer T, Schmermund A. Coronary CT angiography in managing atherosclerosis. Int J Mol Sci., 2015 Feb 9; 16(2): 3740-56.
27. Crosier R, Kafil TS, Paterson DI. Imaging for Cardiovascular Complications of COVID-19: Cardiac Manifestations in Context. Can J Cardiol., 2023 Jun; 39(6): 779-792.
28. Akkaif MA, Bitar AN, Al-Kaif LAIK, Daud NAA, Sha'aban A, Noor DAM, Abd Aziz F, Cesaro A, Sk Abdul Kader MA, Abdul Wahab MJ, Khaw CS, Ibrahim B. The Management of Myocardial Injury Related to SARS-CoV-2 Pneumonia. J Cardiovasc Dev Dis., 2022 Sep 16; 9(9): 307.
29. Watson RA, Johnson DM, Dharia RN, Merli GJ, Doherty JU. Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system. Hosp Pract., (1995). 2020 Oct; 48(4): 169-179.
30. Mahmud E, Dauerman HL, Welt FGP, Messenger JC, Rao SV, Grines C, Mattu A, Kirtane AJ, Jauhar R, Meraj P, Rokos IC, Rumsfeld JS, Henry TD. Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A Position Statement From the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). J Am Coll Cardiol., 2020 Sep 15; 76(11): 1375-1384.
31. Wang W, Wang CY, Wang SI, Wei JC. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: A retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine, 2022 Nov; 53: 101619.
32. Guddeti RR, Yildiz M, Nayak KR, Alraies MC, Davidson L, Henry TD, Garcia S. Impact of COVID-19 on Acute Myocardial Infarction Care. Heart Fail Clin., 2023 Apr; 19(2): 221-229.
33. Huang X, Bai S, Luo Y. Advances in research on biomarkers associated with acute myocardial infarction: A review. Medicine (Baltimore), 2024 Apr 12; 103(15): e37793.
34. Yaluri N, Stančáková Yaluri A, Žeňuch P, Žeňuchová Z, Tóth Š, Kalanin P. Cardiac Biomarkers and Their Role in Identifying Increased Risk of Cardiovascular Complications in COVID-19 Patients. Diagnostics (Basel), 2023 Jul 27; 13(15): 2508.
35. Muscogiuri G, Volpato V, Cau R, Chiesa M, Saba L, Guglielmo M, Senatieri A, Chierchia G, Pontone G, Dell'Aversana S, Schoepf UJ, Andrews MG, Basile P, Guaricci AI, Marra P, Muraru D, Badano LP, Sironi S. Application of AI in cardiovascular multimodality imaging. Heliyon, 2022 Oct 5; 8(10): e10872.
36. Rinaldi R, Basile M, Salzillo C, Grieco DL, Caffè A, Masciocchi C, Lilli L, Damiani A, La Vecchia G, Iannaccone G, Bonanni A, De Pascale G, Murri R, Fantoni M, Liuzzo G, Sanna T, Massetti M, Gasbarrini A, Valentini V, Antonelli M, Crea F, Montone RA, On Behalf Of The Gemelli Against Covid Group. Myocardial Injury Portends a Higher Risk of Mortality and Long-Term Cardiovascular Sequelae after Hospital Discharge in COVID-19 Survivors. J Clin Med., 2022 Oct 10; 11(19): 5964.
37. Filip R, Gheorghita Puscaselu R, Anchidin-Norocel L, Dimian M, Savage WK. Global Challenges to Public Health Care Systems during the COVID-19 Pandemic: A Review of Pandemic Measures and Problems. J Pers Med., 2022 Aug 7; 12(8): 1295.